| Literature DB >> 25941433 |
Ajay Duseja1, Shivaram P Singh2, Vivek A Saraswat3, Subrat K Acharya4, Yogesh K Chawla1, Subhankar Chowdhury5, Radha K Dhiman1, Rohinivilasam V Jayakumar6, Kaushal Madan7, Sri P Misra8, Hrudananda Mishra9, Sunil K Modi10, Arumugam Muruganathan11, Banshi Saboo12, Rakesh Sahay13, Rajesh Upadhyay14.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is closely associated with metabolic syndrome. Prevalence of metabolic risk factors including diabetes mellitus, obesity, etc. is rapidly increasing in India putting this population at risk for NAFLD. Patients with NAFLD are at increased risk for liver-related morbidity and mortality and also cardiovascular disease risk and increased incidence of diabetes mellitus on long-term follow-up. Management of patients with NAFLD may require a multi-disciplinary approach involving not only the hepatologists but also the internists, cardiologists, and endocrinologists. This position paper which is a combined effort of the Indian National Association for Study of the Liver (INASL), Endocrine Society of India (ESI), Indian College of Cardiology (ICC) and the Indian Society of Gastroenterology (ISG) defines the spectrum of NAFLD and the association of NAFLD with insulin resistance and metabolic syndrome besides suggesting preferred approaches for the diagnosis and management of patients with NAFLD in the Indian context.Entities:
Keywords: ALT, Alanine Aminotransferase; APO C3, Apolipoprotein C3; ARFI, Acoustic Radiation Forced Impulse; AST, Aspartate Aminotransferase; ATPIII, Adult Treatment Panel III; BMI, Body mass index; CAD, Coronary artery disease; CC, Cryptogenic Cirrhosis; CIMT, Carotid Intima Media Thickness; CK 18, Cytokeratin 18; CT, Computed Tomography; DM, Diabetes Mellitus; EBP, Enhancer-Binding Protein; EMA, Anti-Endomysial antibodies; FFA, Free Fatty Acids; FMD, Flow-Mediated Vasodilatation; FPG, Fasting Plasma Glucose; GTT, Glucose Tolerance Test; HCC, Hepatocellular Carcinoma; HOMA-IR, Homeostasis Model Assessment for Insulin Resistance; HTG, Hepatic triglyceride; HTN, Hypertension; IFG, Impaired Fasting Glucose; IGT, Impaired Glucose Tolerance; IKK-β, Inhibitor of nuclear factor kappa-B kinase beta; IR, Insulin resistance; IRS-1, Insulin Receptor Substrate-1; ITT, Insulin Tolerance Test; LFTs, Liver Function Tests; MRE, Magnetic Resonance Elastography; MS, Metabolic syndrome; NAFLD; NAFLD, Non-alcoholic fatty liver disease; NASH; NASH, Non-Alcoholic Steatohepatitis; NF-κβ, Nuclear Factor Kappa Β; PCOS, Polycystic Ovarian Syndrome; PPG, Post-Prandial Glucose; PROCAM, Prospective Cardiovascular Munster study; SREBP, Sterol-Regulatory Element-Binding Protein; T2DM, Type 2 Diabetes Mellitus; TE, Transient elastography; TG, Triglycerides; TTG, Anti-tissue transglutaminase; VHCC, Virus-related HCC; VLDL, Very Low Density Lipoprotein; WHO, World Health Organization; cryptogenic cirrhosis; insulin resistance; nonalcoholic steatohepatitis
Year: 2015 PMID： 25941433 PMCID： PMC4415196 DOI： 10.1016/j.jceh.2015.02.006
Source DB: PubMed Journal: J Clin Exp Hepatol ISSN： 0973-6883